Alex G. Lee, Ph.D. Esq.’s Post

"The path to equitable neurological patient engagement is complex and requires a multifaceted approach. This includes diversifying clinical trial locations and decentralizing the clinical trial data collection so that we not only invite diverse populations to participate in clinical trial design and recruitment efforts but that we also remove the barriers that prevent their participation." Read more below on how UCB is improving #diversity in neurological clinical trials. #pharma #innovation

Changes in #brainstructure and more precisely the #microstructure is essential in any #neuromodulation therapy. Using world leading measures of #neurodegeneration like CDM, combined with pioneering method from world class collaborators at Fondazione Santa Lucia (Giacomo Koch), Harvard Medical School & Mass General Brigham (Emiliano Santarnecchi), you produce some amazing work and pave the way to really helping #alzheimer patients around the world. A huge thank you to all the authors. We are proud of our partnership here and look forward to continuing to support this intervention right through to regulatory approval. 😊 🇮🇹 🇬🇧 🇺🇸 Our new paper "Macro and micro structural preservation of grey matter integrity after 24 weeks of rTMS in Alzheimer’s disease patients: a pilot study" is now available online via the link below. https://lnkd.in/gDAP56w4 Sinaptica Therapeutics #rTMS #innovation #neurodegeneration #alzheimersdisease #cortex #precunus #MRI #Diffusion #Dementia #noninvasive #neuroplasticity

New paper: "Macro and micro structural preservation of grey matter integrity after 24 weeks of rTMS in Alzheimer’s disease patients: a pilot study"

Go further than macrostructure. Cortical Disarray Measurement (CDM) was able to find changes in grey matter #microstructure using #SinapticaTherapeutics neuromodulatory therapy. Check our our paper below. #neurodegeneration #alzheimersdiease #diffusionMRI

How is biotech pioneering new patient options for endometriosis? 🚀 Affecting around 190 million women and girls, endometriosis is a condition that has been rather difficult to treat with no cures to date. 📅 It is caused by the growth of tissue outside the uterus, leading to debilitating pelvic pain during sex and heavy periods. With some clinical trials showing promise and with the discovery of new drug targets, there is hope for better endometriosis care. 💊 Read our latest article to find out about some of the recent advancements in endometriosis research! 👇 https://lnkd.in/dXAXCu7w #endometriosis #biotechinnovation #womenshealth #clinicaltrials #medicalresearch #healthcareinnovation #biotechnews Bruce Nicholson | Hera Biotech | The University of Edinburgh | TiumBio | Serac Healthcare | Western Sydney University | FimmCyte | Celmatix

Alongside the many breakthroughs in the #Alzheimers #DrugDevelopment space, the diagnostics landscape is rapidly evolving, too. Researchers are exploring ways to improve the accessibility and scalability of #amyloid blood tests, and working to validate the complementary #biomarkers that will support drug development. Our Co-Founder and Chief Science Officer, Howard Fillit, MD, connected with Rowan Walrath of C&EN to discuss the ADDF's Diagnostics Accelerator (DxA) and its funding of blood-based biomarkers and #digital diagnostic tools, offering his prediction that #BloodTests will eventually replace the current gold standard PET scans and spinal taps for Alzheimer's #diagnosis. Throughout the article, diagnostic and biomarker research by ADDF- and DxA-funded investigators and biotechs like C2N Diagnostics, ALZpath Inc., Quanterix, RetiSpec, Rhoda Au, and DiaMiR Bio are mentioned. Read the full article here: https://bit.ly/3JaGZXR

In STRIVE, natalizumab treatment demonstrated effectiveness in clinical, magnetic resonance imaging (MRI), and patient-reported outcomes (PROs) in patients with early relapsing-remitting multiple sclerosis (RRMS). This post hoc analysis examined the effectiveness and safety of natalizumab in patients who self-identified as either Black/African American (AA) or Hispanic/Latino. Read more on the research conducted by Northwestern's Dr Roumen Balabanov investigating the impact of a #multiplesclerosis treatment in #AfricanAmerican and #Hispanic / #Latinx patients: https://lnkd.in/g2DhRKZP #Chicago #Chicagoland

A breakthrough study by National Institutes of Health researchers has uncovered a potential therapeutic target for dry AMD, a leading cause of vision loss. This discovery sheds light on the cellular processes behind retinal degeneration and opens doors to new treatments. Click to to learn more: https://lnkd.in/e7m_QcE7   Let us know your thoughts in the comments! #medicalresearch #clinicaltrials #medicalstudies #miamiclinicalresearch #nihresearch #eyedisease #amdawareness #retinalhealth #visionloss #retinalresearch #visionresearch #eyehealth

Breaking news 🧠 Eli Lilly and Company Kisunla™ is FDA approved for the treatment of early symptomatic Alzheimer's disease, offering patients a way to slow the disease's progression, and improve their quality of life. "Kisunla demonstrated very meaningful results for people with early symptomatic Alzheimer's disease, who urgently need effective treatment options. We know these medicines have the greatest potential benefit when people are treated earlier in their disease, and we are working hard in partnership with others to improve detection and diagnosis," said Anne White, and President of Lilly Neuroscience International Medical Imaging companies play a critical role in the analysis of brain scans for Neurodegenerative disease markers. Aside from the big names, younger companies like Qynapse, Cortechs.ai, icometrix, Oxford Brain Diagnostics Ltd, Darmiyan , Vistim Labs and others work tirelessly to support the positive patient impact of drugs like Kisunla! #earlydetection #medicalimaging #artificialintelligence

📣 Breaking News in Alzheimer's Treatment Eli Lilly and Company's Kisunla (donanemab) has been approved for treating early symptomatic Alzheimer's Disease! This new treatment option offers patients a way to slow the disease's progression, and improve their quality of life. 💉 Kisunla has shown remarkable phase III trial results, reducing cognitive and functional decline by up to 35% in its Phase 3 trial, and boasts a convenient monthly infusion schedule. It is the only drug on the market that supports stopping treatment once amyloid plaques are removed, though it has a higher rate of Amyloid Related Imaging Abnormalities (ARIA). 🧠 At Cortechs.ai, we are at the forefront of ARIA management with our 510k-pending NeuroQuant ARIA technology. NeuroQuant ARIA is an advanced AI-driven solution designed to assist healthcare professionals in detecting and monitoring ARIA with precision. Our NeuroQuant ARIA reports deliver comprehensive and detailed analysis, helping doctors make informed decisions and mitigate potential risks associated with ARIA. #AI #AlzheimersDisease #AD #ARIA #radiology